Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer.

ABSTRACT:

Background

Selinexor (KPT-330) is an oral agent that has been shown to inhibit the nuclear exporter XPO1. Given the pressing need for novel therapies for triple-negative breast cancer (TNBC), we sought to determine the antitumor effects of selinexor in vitro and in vivo.

Methods

Twenty-six breast cancer cell lines of different breast cancer subtypes were treated with selinexor in vitro. Cell proliferation assays were used to measure the half-maximal inhibitory concentration (IC₅₀) and to test the effects in combination with chemotherapy. In vivo efficacy was tested both as a single agent and in combination therapy in TNBC patient-derived xenografts (PDXs).

Results

Selinexor demonstrated growth inhibition in all 14 TNBC cell lines tested; TNBC cell lines wer

SUBMITTER: Arango NP 

PROVIDER: S-EPMC5557476 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature